BioLife Solutions (BLFS) Expected to Announce Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS) is expected to post its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect BioLife Solutions to post earnings of ($0.01) per share and revenue of $25.6910 million for the quarter. BioLife Solutions has set its FY 2025 guidance at EPS.Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The company had revenue of $25.42 million during the quarter, compared to the consensus estimate of $23.71 million. On average, analysts expect BioLife Solutions to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioLife Solutions Price Performance

Shares of BioLife Solutions stock opened at $27.11 on Wednesday. BioLife Solutions has a fifty-two week low of $19.10 and a fifty-two week high of $29.62. The firm has a fifty day moving average price of $26.45 and a two-hundred day moving average price of $23.99. The company has a market cap of $1.30 billion, a PE ratio of -225.90 and a beta of 1.95.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BLFS. Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. HC Wainwright reissued a “buy” rating and issued a $32.00 price target (up from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Stephens assumed coverage on shares of BioLife Solutions in a report on Tuesday, July 22nd. They issued an “overweight” rating and a $30.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.29.

Insider Activity at BioLife Solutions

In other news, CMO Todd Berard sold 10,000 shares of the firm’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $25.53, for a total transaction of $255,300.00. Following the completion of the transaction, the chief marketing officer directly owned 124,618 shares of the company’s stock, valued at approximately $3,181,497.54. This trade represents a 7.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Casdin Partners Master Fund, L sold 750,000 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $28.55, for a total transaction of $21,412,500.00. Following the transaction, the insider directly owned 5,957,165 shares of the company’s stock, valued at $170,077,060.75. The trade was a 11.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,807,742 shares of company stock worth $46,467,584 in the last ninety days. Company insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds have recently made changes to their positions in the company. Strs Ohio acquired a new stake in shares of BioLife Solutions during the 1st quarter worth about $153,000. Tower Research Capital LLC TRC increased its position in shares of BioLife Solutions by 547.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,133 shares of the medical equipment provider’s stock worth $154,000 after purchasing an additional 6,032 shares in the last quarter. Man Group plc acquired a new stake in shares of BioLife Solutions during the 2nd quarter worth about $234,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of BioLife Solutions during the 1st quarter worth about $283,000. Finally, BNP Paribas Financial Markets increased its position in shares of BioLife Solutions by 59.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 18,755 shares of the medical equipment provider’s stock worth $404,000 after purchasing an additional 6,997 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.